Altos Biologics has completed patient enrolment in a global Phase 3 clinical trial of ALT-L9, an Eylea biosimilar for neovascular (wet) age-related macular degeneration

UNSW Medicine and Health has created a new series of short courses to equip health professionals, clinicians, and non-clinicians with skills needed to boost

Frontera Therapeutics has dosed its first patients in a gene therapy trial for the treatment of X-Linked retinitis pigmentosa (XLRP).

The inaugural Optical Dispensers Australia (ODA) industry conference takes place in Sydney from 28–29 April 2023.